

## CHEPLAPHARM REACHED THE FINAL PHASE OF THE AXIA AWARDS

*According to the motto "We are creating a future with perspectives", mid-sized companies were honored for their sustainable and successful management by Deloitte and WirtschaftsWoche, together with the BDI, with the Axia Award.*



Sebastian F. Braun, Managing Director of CHEPLAPHARM Arzneimittel GmbH in Greifswald, is proud to be one of the finalists at the "Axia Award 2017" in Düsseldorf on November 29, 2017 - a prestigious business award recognizing entrepreneurial excellence in SMEs. "This recognition is a great success for us, because we see it as a confirmation of our consistent work to further develop CHEPLAPHARM through sustainable and profitable growth," says Braun.

Medium-sized companies, with their company headquarters in Germany and an annual turnover of at least 150 million euros, were allowed to apply. Since CHEPLAPHARM plans to generate sales of 250 million euro in 2017, the company already applied for the highly-coveted business prize in July.

Out of numerous applications, Axia Award winners in four different categories were selected in an extensive selection process by an independent, highly qualified jury of experts. A total of 31 companies with an average turnover of more than 600 million euros, among them globally known companies that are offering branded products and many niche market leaders of the German economy, reached the final stage - including CHEPLAPHARM.

The young pharmaceutical company makes an important contribution to strengthening the economic power and offering valuable jobs in Mecklenburg-Western Pomerania. "CHEPLAPHARM is like a lighthouse in the region and receives a lot of support from the city of Greifswald and other institutions," explains Sebastian F. Braun (CEO).

The structure, however, differs greatly from other mid-sized pharmaceutical companies, as the company grows by acquiring pharmaceutical products on a global level and because it has no own research & development and production. The successful performance and growth result mainly from the fact that CHEPLAPHARM has established and fostered its relationships with reliable financiers and more than 100 sales and distribution partners worldwide.

"Although CHEPLAPHARM was not among the winners, it nevertheless reached the final round of the Axia Awards, which is a great success for a family-run pharmaceutical company with headquarters in Mecklenburg-Western Pomerania. This is a great success and a solid foundation for future developments," summarizes Braun.

### **Press Office:**

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)